Long-term follow-up study of RV001V
Latest Information Update: 24 Mar 2023
At a glance
- Drugs Onilcamotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 10 Feb 2023 According to a CHOSA Oncology media release, RhoVac AB changes name to CHOSA Oncology AB.
- 21 Jun 2021 New trial record
- 09 Jun 2021 According to a RhoVac media release, the company has received full approvals to initiate this follow-up study in coming months.